The Labyrinth of Product Development and Regulatory Approvals in Liquid Biopsy Diagnostics
Author:
Open Access
- 4 June 2019
- journal article
- review article
- Published by Wiley in Clinical and Translational Science
- Vol. 12 (5) , 431-439
Abstract
The evolution of chemistries and instrument platforms for next‐generation sequencing has led to sequencing of genomic variants in both tumor biopsies as well as in circulating tumor cells (CTCs) and cell‐free DNA liquid biopsies. The transition of these analytical platforms into clinical ones has led to challenges in product development as well as regulatory strategies for the approval of diagnostic products with these platforms. Regulatory strategies for liquid biopsy diagnostics depend on a framework that has been developed over the past few years by the US Food and Drug Administration (FDA). This framework includes both guidances that cover enrichment biomarkers and companion diagnostics, as well as regulatory approval precedents, which can be used to design regulatory strategies for new liquid biopsy diagnostic products. However, the regulatory paths for these liquid biopsy diagnostics can also be tortuous, as is the example of CTC—platform liquid biopsies. The ultimate success of regulatory pathways of liquid biopsy diagnostics has been driven by the incremental value of FDA approval for Clinical Laboratory Improvement Amendment (CLIA)‐developed tests and by the inherent complexity of these diagnostics, which are practical barriers for the widespread replication of these tests throughout CLIA laboratories. The framework for FDA approval of sequence information from these liquid biopsies has been focused on single‐site approvals of diagnostics where sequencing information is considered at different diagnostic risk levels, ranging from novel or follow‐on companion diagnostics to variant calls in genomic targets considered independently valuable for therapeutic decision making.Keywords
This publication has 37 references indexed in Scilit:
- Size-selective collection of circulating tumor cells using Vortex technologyLab on a Chip, 2013
- TMPRSS2-ERG Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated With Abiraterone AcetateEuropean Urology, 2011
- Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect™ versus Veridex CellSearch™ systemInternational Journal of Cancer, 2011
- Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibodyLab on a Chip, 2009
- The CTC-Chip: An Exciting New Tool to Detect Circulating Tumor Cells in Lung Cancer PatientsJournal of Thoracic Oncology, 2009
- Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate CancerClinical Cancer Research, 2007
- Circulating Tumor Cell Analysis in Patients with Progressive Castration-Resistant Prostate CancerClinical Cancer Research, 2007
- The drug diagnostic co-development concept paperThe Pharmacogenomics Journal, 2006
- Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast CancerNew England Journal of Medicine, 2004
- Biomarkers and surrogate endpoints: Preferred definitions and conceptual frameworkClinical Pharmacology & Therapeutics, 2001